^
Association details:
| Biomarker: | FGFR1 mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...FGFR3 mutations (urothelial), and FGFR3 fusions/rearrangements (mostly CNS tumors...In addition, patients with tumors harboring FGFR2 amplifications (gastric and breast cancer), FGFR1 fusions/rearrangements (primary CNS and head and neck cancer), and FGFR1 mutations (urothelial cancer) also had targetlesion shrinkage...Futibatinib demonstrated activity in urothelial carcinoma (with responses in patients harboring FGFR3 or FGFR1 mutations), showing an ORR of 16% and DCR of 47%...
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
